雅培(Abbott)公司Absolute Pro®支架系统获FDA批准

2012-03-08 MedSci 生物谷bioon.com

2012年3月7日,雅培(Abbott)公司今天宣布,FDA批准其Absolute Pro血管自膨式支架系统(Absolute Pro? Vascular Self-Expanding Stent System)用于髂总动脉疾病(iliac artery disease)的治疗,这是一种周边动脉疾病(peripheral artery disease,PAD),能影响患者的双下肢。 随着时间的推

2012年3月7日,雅培(Abbott)公司今天宣布,FDA批准其Absolute Pro血管自膨式支架系统(Absolute Pro? Vascular Self-Expanding Stent System)用于髂总动脉疾病(iliac artery disease)的治疗,这是一种周边动脉疾病(peripheral artery disease,PAD),能影响患者的双下肢。

随着时间的推移,髂动脉疾病的进展能导致患者丧失行走能力、经历慢性疼痛及遭受永久性残疾。Absolute Pro的审批是基于一项MOBILITY((Omnilink Elite? or Absolute Pro Stent用于髂总动脉)研究,该研究证实,Absolute Pro是安全有效的,甚至在伴有复杂疾病的患者中亦如此。

"髂动脉疾病极大地影响了患者的整个生活质量,"MOBILITY试验首席研究员Tony S. Das医师说道。"治疗的目的是,打开狭窄的髂总动脉,恢复腿部的血液流动,从而减轻患者的疼痛并改善患者的生活质量,让他们能走的更远,并享受积极的生活。有了Absolute Pro,美国医生现在又多了一项选择,来对这些患者进行安全有效的治疗。"

Absolute Pro是一种自膨式镍钛支架系统,由弹性材料制成,能够顺应病变部位的损伤。它采用先进的支架可视性技术及一种精心设计的递送系统,能最大限度地减少支架部署过程中的摩擦,并确保支架精确地置入病变部位

编译自:Bio-Medicine
http://www.bio-medicine.org/medicine-technology-1/Abbotts-Absolute-Pro-AE-Vascular-Self-Expanding-Stent-System-Receives-FDA-Approval-for-Treatment-of-Iliac-Artery-Disease-24516-1/

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839142, encodeId=28d01839142c1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Oct 09 09:35:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4218, encodeId=1b3f421802, content=These pieces raelly set a standard in the industry., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ozkar, createdTime=Mon Apr 23 02:58:00 CST 2012, time=2012-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579904, encodeId=952715e99046d, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Sat Mar 10 13:35:00 CST 2012, time=2012-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601658, encodeId=c42c1601658ae, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 10 13:35:00 CST 2012, time=2012-03-10, status=1, ipAttribution=)]
    2012-10-09 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839142, encodeId=28d01839142c1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Oct 09 09:35:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4218, encodeId=1b3f421802, content=These pieces raelly set a standard in the industry., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ozkar, createdTime=Mon Apr 23 02:58:00 CST 2012, time=2012-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579904, encodeId=952715e99046d, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Sat Mar 10 13:35:00 CST 2012, time=2012-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601658, encodeId=c42c1601658ae, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 10 13:35:00 CST 2012, time=2012-03-10, status=1, ipAttribution=)]
    2012-04-23 ozkar

    These pieces raelly set a standard in the industry.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1839142, encodeId=28d01839142c1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Oct 09 09:35:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4218, encodeId=1b3f421802, content=These pieces raelly set a standard in the industry., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ozkar, createdTime=Mon Apr 23 02:58:00 CST 2012, time=2012-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579904, encodeId=952715e99046d, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Sat Mar 10 13:35:00 CST 2012, time=2012-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601658, encodeId=c42c1601658ae, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 10 13:35:00 CST 2012, time=2012-03-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839142, encodeId=28d01839142c1, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Oct 09 09:35:00 CST 2012, time=2012-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4218, encodeId=1b3f421802, content=These pieces raelly set a standard in the industry., beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ozkar, createdTime=Mon Apr 23 02:58:00 CST 2012, time=2012-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579904, encodeId=952715e99046d, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Sat Mar 10 13:35:00 CST 2012, time=2012-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601658, encodeId=c42c1601658ae, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 10 13:35:00 CST 2012, time=2012-03-10, status=1, ipAttribution=)]
    2012-03-10 sunylz